A case of seriously sore back after Denosumab discontinuation

被引：0
|
作者：
Lo, Yu-Chin [1 ]
Sinha, Ashim [1 ]
McLean, Anna [1 ]
Ganda, Kirtan [2 ]
机构：
[1] Queensland Hlth, Cairns North, Qld, Australia
[2] Concord Hosp, Endocrine Unit, Sydney, NSW, Australia
来源：
CLINICAL ENDOCRINOLOGY | 2018年 / 89卷
关键词：
POSTMENOPAUSAL WOMEN;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
244
引用
收藏
页码：72 / 72
页数：1
相关论文
共 50 条
  • [41] Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis
    Ebina, Kosuke
    Hashimoto, Jun
    Kashii, Masafumi
    Hirao, Makoto
    Miyama, Akira
    Nakaya, Hiroyuki
    Tsuji, Shigeyoshi
    Takahi, Koichiro
    Tsuboi, Hideki
    Okamura, Gensuke
    Etani, Yuki
    Takami, Kenji
    Yoshikawa, Hideki
    MODERN RHEUMATOLOGY, 2021, 31 (02) : 485 - 492
  • [42] Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis
    Niimi, R.
    Kono, T.
    Nishihara, A.
    Hasegawa, M.
    Kono, T.
    Sudo, A.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 (03) : 769 - 772
  • [43] Generation of humanized RANKL mice to study rebound resorption after discontinuation of Denosumab
    Fu, Qiang
    Bustamante-Gomez, Cecile
    Guha, Anveshi
    Gubrij, Igor
    O'Brien, Charles
    JOURNAL OF BONE AND MINERAL RESEARCH, 2020, 35 : 256 - 256
  • [44] Discontinuation of denosumab in men with prostate cancer
    Solling, Anne Sophie
    Harslof, Torben
    Brockstedt, Helle Kongsbak
    Langdahl, Bente
    OSTEOPOROSIS INTERNATIONAL, 2023, 34 (02) : 291 - 297
  • [45] CASCADE OF VERTEBRAL FRACTURES IN AN OSTEOPOROTIC WOMAN ONE YEAR AFTER DISCONTINUATION OF DENOSUMAB
    Sanchez, Ariel
    Carlos Raggio, Juan
    Valtorta, Emiliano
    REVISTA MEDICA DE ROSARIO, 2018, 84 (01): : 22 - 25
  • [46] Oral vs Intravenous Bisphosphonates for Preventing Bone Loss After Denosumab Discontinuation
    Dickens, Laura
    Vokes, Tamara
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 : 182 - 183
  • [47] Follistatins, activins and inhibins during osteoporosis therapy with denosumab or zoledronate and after their discontinuation
    Anastasilakis, Athanasios D.
    Makras, Polyzois
    Polyzos, Stergios A.
    Kumar, Ajay
    Kalra, Bhanu
    Mantzoros, Christos S.
    DIABETES OBESITY & METABOLISM, 2025, 27 (04): : 2288 - 2293
  • [48] Hypercalcemia in Children Following a Discontinuation of Denosumab Therapy: A Case Report and Literature Review
    Liu, Xu
    Xie, Yanshu
    Tang, Jing
    Zhong, Jingzi
    Lan, Dan
    CLINICAL PEDIATRICS, 2024, 63 (06) : 750 - 754
  • [49] Healing of osteonecrosis of the jaw (ONJ) after discontinuation of denosumab in a patient with bone metastases of colorectal cancer: A case report and hypothesis
    Ohga, Noritaka
    Yamazaki, Yutaka
    Tsuboi, Kanako
    Kitagawa, Yoshimasa
    QUINTESSENCE INTERNATIONAL, 2015, 46 (07): : 621 - 626
  • [50] Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation
    Fu, Qiang
    Bustamante-Gomez, Nancy C.
    Reyes-Pardo, Humberto
    Gubrij, Igor
    Escalona-Vargas, Diana
    Thostenson, Jeff D.
    Palmieri, Michela
    Goellner, Joseph J.
    Nookaew, Intawat
    Barnes, C. Lowry
    Stambough, Jeffrey B.
    Ambrogini, Elena
    O'Brien, Charles A.
    JCI INSIGHT, 2023, 8 (18)
12345